Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
Age
21–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with hypertension that have newly started using Valsartan+/-HCTZ
You may not be if
Pregnancy or Hypersensitivity to Valsartan+/-HCTZ
Clareo Health | Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months
